
Why are experts sceptical of the small HBOT studies?
With 34 patients, a study cannot detect a three percentage point difference in graft survival. Five patients with no one to compare against cannot show that anything is due to the treatment.
With only 34 participants, it is impossible to detect a three percentage point difference in graft survival. A case series of five patients with no control group cannot link anything at all to the treatment. The doubts about HBOT with hair transplants concern how small the studies are and how they were designed. They do not say the treatment is implausible.
Is scepticism about HBOT the same as saying it doesn't work?
No. The mechanism is logical, hyperbaric medicine is a serious field, and the only randomised trial found real differences in two of the outcomes. The criticism is narrower than that. The research is too small and too thin to carry the claims hung on it. It is the extent of the evidence that is being criticised, not the idea behind the treatment.
Why couldn't the HBOT study detect a small difference in survival?
With 17 patients per arm, a small effect disappears in random variation. After nine months, survival was 96.9 % with HBOT and 93.8 % without. The gap of around three points was not statistically significant. To detect a difference that small between two proportions around 95 %, you need several hundred patients per group. The study was never sized for that question.
This is the very core of the issue, and it is worth understanding. It applies to almost every add-on sold in this field, not just HBOT.
Fan and colleagues randomised 34 patients into two equal groups of 17. After nine months, the HBOT group had 96.9 % survival and the control group 93.8 %. The gap was about three percentage points, and in the analysis it was not statistically significant.
A finding like that can be read in two very different ways. Perhaps there is no difference. Or perhaps there is a real three-point difference that was lost in the noise because the groups were so small. When both groups are close to 95 %, several hundred participants per group are needed to detect something that small. Seventeen is not enough. With so few participants, you would almost never get a significant finding for survival, whatever the reality.
This cuts both ways. The study does not show that HBOT improves survival. Nor does it show the opposite. It simply was not designed to answer this. Using 96.9 % as proof of benefit is therefore just as wrong as using the null finding as proof that there is no benefit.
Why is the shedding finding more reliable than the survival finding?
Because large differences can be detected even in small groups, while a null finding for survival says nothing in either direction. Early shedding affected 27.6 % with HBOT and 69.1 % without. Itching or folliculitis affected 11.8 % and 35.3 %. Both differences are large and credible. HBOT probably reduces early shedding and inflammation, but whether it leads to more follicles surviving, no one knows.
The most striking result in the study was early shedding. In the HBOT group 27.6 % shed, in the control group 69.1 %. That is a large gap, and large gaps can be detected even with few participants. Itching and folliculitis show the same pattern: 11.8 % in the HBOT group and 35.3 % among the controls.
So the positive findings are more reliable than the null finding is informative. A reasonable reading is that HBOT probably leads to less early shedding and fewer inflammatory complaints after the operation. What that means for how many grafts ultimately survive, we do not know.
That leaves the question of what less shedding actually means. It is normal for the transplanted hair shaft to fall out after the procedure. It is part of the hair cycle, and the follicle usually lives on and produces a new hair. Less visible shedding makes the time after surgery easier for the patient. Whether it also means more surviving follicles is exactly what the survival measure was meant to answer, and it failed to do so.
What methodological objections to the HBOT study have been published?
In a letter, Dong and Jin raised two points. The study did not show whether the outcomes differed for men and women, which they called indispensable because androgen levels are so different. Nor did it say how hair loss medicines were handled in the criteria for excluding patients, even though finasteride and minoxidil affect shedding, the outcome with the largest effect. Both points remain unanswered.
After the study came out, Dong and Jin sent a letter to the Journal of Cosmetic Dermatology. They had two specific objections.
- No analysis by sex. The article did not make clear whether the difference between the groups was the same for men and women. Given such large differences in androgen levels, the letter writers considered this essential for assessing the study.
- Unclear about medication use. It was not clear how hair loss medicines were handled when patients were excluded. Finasteride and minoxidil affect shedding, and shedding was precisely where the study found its largest effect. That is no minor detail.
Answers to these points never came in the published exchange.
Why is the case report on five patients not strong evidence?
Because there was no control group. All five received HBOT. The scabs were gone by day three to five, 97 to 99 % of the grafts took, and the patients had recovered after 2.8 days. None of this can therefore be linked to the treatment. An ordinary FUE without complications often heals just as quickly with no add-ons at all. A case series like this can generate a hypothesis, but never show an effect.
The 2025 report in Cureus on five patients is often mentioned alongside the randomised trial, as if it confirmed the findings. It does not, and the difference matters.
All five received HBOT. None went without. The scabs were gone after three to five days, the grafts were reported to have taken in 97 to 99 % of cases, recovery took 2.8 days on average, and no one had complications.
Without a control group, you have nothing to measure the observations against. Scabs come off on their own within a few days. Most people are back to normal just as quickly. And after an uncomplicated FUE, almost all grafts take, even without add-ons. Reports of this kind can put forward a hypothesis and say something about safety. They cannot show that something works.
What did the study of HBOT in healthy volunteers find?
Lee and colleagues had nine healthy people undergo 50 HBOT sessions over three months. Follicle density, the number of hairs per follicle and hair volume showed a tendency to increase, but none of the changes were significant. The hair shafts, on the other hand, became significantly thinner, which the researchers interpreted as early regrowth. They themselves call the findings preliminary. That is an argument for a larger study, not for selling the treatment.
What can the HBOT research honestly be used to say?
Based on one small study, you can say that HBOT probably leads to less early shedding and fewer cases of itching or folliculitis. You cannot say that HBOT gives more surviving grafts, a better result after twelve months, a lower risk of tissue death or less swelling, or that it helps smokers and people with diabetes. None of this has been shown, and some of it no one has even tried to measure.
Sources
- Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
- Dong X, Jin X. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia [letter to the editor]. Journal of Cosmetic Dermatology, 2021. doi.org/10.1111/jocd.14131
- Giardiello F, De Medeiros Quirino L, Brigante R, Chumak M. Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation. Cureus, 2025;17(12):e99635. doi.org/10.7759/cureus.99635
- Lee HY, Lee JY, Kim SC, Lee Y. Preliminary Effects of Hyperbaric Oxygen Therapy on Hair Follicle Characteristics in Healthy Subjects. Bioengineering, 2026;13(2):240. doi.org/10.3390/bioengineering13020240
- Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and Reconstructive Surgery, 2011;127 Suppl 1:131S-141S. pubmed.ncbi.nlm.nih.gov/21200283
This article summarises published research and common clinical practice. It is meant as general information and is not medical advice. Nor does it replace the advice you get from your own surgical team. If your team tells you something different from what is written here, follow your team.
Wondering what's possible for your hair?
Send three sharp photos of your hair, from the front, the top and the back. You'll get an honest answer on what can be done, roughly how many grafts it would take and what it costs.
- Free and with no obligation
- Photos are assessed by the clinic's medical team
- Replies usually within an hour in the daytime
A study tells you something about groups. Only a doctor who has seen your photos can say what applies to your hair. The medical team at the clinic at the top of our ranking offers a free assessment.
Goes to the clinic at the top of our ranking.

